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INTRODUCTION
Ulcerative colitis (UC) is an inflammatory bowel disease that 
results in chronic inflammation of the large intestine due to 
immune dysregulation.1 UC is an incurable disease with alter-
nating periods of remission and relapse. Due to this chronic 
clinical course, most patients with UC require life-long medi-
cal treatment. The medical treatment of UC has changed dra-
matically over the past decade, with the introduction of biolog-
ical agents that target tumor necrosis factor-alpha (TNF-α).2 
Pivotal randomized controlled trials (RCTs) demonstrated the 
efficacy of anti-TNF agents, including infliximab, adalimum-
ab, and golimumab, for inducing and maintaining remission 
in patients with moderately to severely active UC.3-6 Anti-TNF 
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therapy targeting mucosal healing may also lead to changes in 
the natural course of UC. Indeed, previous RCTs demonstrat-
ed that anti-TNF therapy reduces the risk of colectomy and 
hospitalization.7,8
However, the optimal timing of anti-TNF initiation in UC 
patients remains a challenging issue. Several studies have 
proven the benefit of earlier anti-TNF initiation on the clinical 
outcomes of patients with Crohn’s disease (CD),9-11 while very 
little is known about the effects of earlier anti-TNF initiation 
on the natural history of UC. The results of CD patients may not 
be generalized for UC patients, as the two diseases have differ-
ent features. To date, only a few studies have examined the ef-
fect of earlier anti-TNF initiation on the clinical outcomes of 
UC.12-14 However, the number of UC patients included in pre-
vious studies was insufficient to draw a clear conclusion. Fur-
thermore, all previous studies on this topic were performed in 
Western countries,12-14 and their results may not be generaliz-
able in Asian UC patients. To better understand the association 
between anti-TNF initiation timing and clinical outcomes of 
UC, an analysis of population-based Asian data of a large num-
ber of patients is warranted.
Therefore, in this nationwide population-based study of 
data from the South Korean health insurance claims database, 
we evaluated the impact of early initiation of anti-TNF therapy 
on the clinical outcomes [abdominal surgery, UC-related emer-
gency room (ER) visits, UC-related hospitalization, and new 
corticosteroid use] of patients with UC during maintenance 
therapy in the real-life clinical setting. 
MATERIALS AND METHODS
Study design and data source 
This study analyzed data from the National Health Insurance 
(NHI) claims database of South Korea, a mandatory nation-
wide health insurance program established by the Korean 
government that covers all forms of health-care utilization, in-
cluding outpatient care, pharmaceutical services, and hospital-
ization, for the entire population of South Korea (approximately 
51 million people). Medical institutions must electronically sub-
mit all information regarding health-care utilization for reim-
bursement; this information is registered in a comprehensive 
database operated by the Health Insurance and Review Agen-
cy (HIRA). The HIRA database contains information on per-
sonal demographics, outpatient and inpatient medical use, 
prescriptions, diagnostic and surgical procedures, as well as 
diagnoses identified by the International Classification of Dis-
eases 10th revision (ICD-10) codes.15-17 The source population 
for this study was NHI claims data registered between 2008 
and 2016. 
Patient ascertainment and definitions 
To improve the diagnostic accuracy of UC, only patients with 
data on both appropriate diagnostic codes and UC-related 
medicine prescriptions were included. The ICD-10 codes 
K51.0–51.9 indicate UC. UC-related medicine prescriptions 
were defined as prescriptions of 5-aminosalicylic acids (5-ASA) 
for ≥1 month, immunomodulators (azathioprine or 6-mer-
captopurine) at least once, and/or biologics at least once.15-17 
To rule out the use of drugs for other autoimmune diseases, 
the included medications were confined to prescriptions re-
ceived from a gastroenterology clinic. During the study period, 
the biologics approved for UC treatment in South Korea were 
infliximab, adalimumab, and golimumab. However, the actual 
use of golimumab was rare during the study period, as this an-
ti-TNF agent was only approved in May 2015. 
The date of UC registration in the HIRA database was con-
sidered as the date of diagnosis. Given that previous prevalent 
cases could confound the incidence rate, we set a washout pe-
riod of 2 years; as a result, patients who were diagnosed with 
UC from January 1, 2010 to December 31, 2016 were analyzed. 
Patients were stratified by the time to their first dose of in-
duction anti-TNF agent after diagnosis. Based on the previous 
studies,13,14,18 early initiation of anti-TNF therapy was defined 
as starting infliximab, adalimumab, or golimumab within 2 
years of diagnosis, whereas late initiation of anti-TNF therapy 
was defined as starting >2 year after diagnosis. 
To properly assess the effectiveness of anti-TNF therapy on 
long-term clinical outcomes, patients who received anti-TNF 
therapy for less than 6 months were excluded from the analy-
sis. Since the effects of anti-TNF therapy may differ between 
patients undergoing colectomy or not, patients with a history of 
colectomy before starting anti-TNF therapy were also excluded 
from the analysis.
Clinical outcomes 
The primary objective of this study was to determine if the 
early initiation of anti-TNF therapy within 2 years of UC diag-
nosis affected the need for colectomy, UC-related ER visits, 
UC-related hospitalization, or new corticosteroid use during 
anti-TNF maintenance therapy. These clinical outcomes were 
determined based on the previous studies.12-14 Colectomy was 
identified using the procedural code. ER visits were defined as 
patient visits to the ER with UC as the primary diagnosis. Hos-
pitalization was defined as admission for ≥3 days in the de-
partment of gastroenterology. Finally, new corticosteroid use 
was defined as moderate to high dose of corticosteroid use 
(≥30 mg prednisolone, ≥50 mg methylprednisolone, or ≥200 
mg hydrocortisone) for more than 2 months after the first anti-
TNF agent prescription. 
Statistical analysis
Incidence rates for colectomy, ER visits, hospitalization, and 
corticosteroid use were calculated per 100 person-years with 
95% confidence intervals (CIs) using Poisson distribution. The 
crude risk of outcomes between early and late initiators was 
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compared using Kaplan-Meier method and log-rank tests. We 
used Cox proportional hazards models to adjust for potential 
confounding variables. Baseline covariates including sex, age, 
first anti-TNF agent, region, and hospital scale were adjusted 
as time-fixed covariates. The cumulative use period of anti-
TNF agents and concomitant medications, including 5-ASA 
and immunomodulators, were adjusted as time-dependent 
covariates. The results are presented as hazard ratios (HRs) 
with corresponding 95% CIs. All analyses were performed using 
the SAS Enterprise Guide (SAS Institute, Inc., Cary, NC, USA), 
and p-values<0.05 were considered statistically significant.
Ethical considerations
As the information in the HIRA database is encrypted, the da-
tabase does not contain personal identifiers. The study proto-
col was approved by the Institutional Review Board of Sever-




We identified that 17167 patients were diagnosed with UC in 
2010–2016; among them, 1125 patients started their first anti-
TNF agents during the study period. Of these 1125 patients, 
419 were excluded as they received anti-TNF therapy for less 
than 6 months, while another 8 were excluded for having un-
dergone colectomy before the start of anti-TNF therapy. Ulti-
mately, 698 patients were included in the study, of whom 399 
were early initiators of anti-TNF (≤2 years) and 299 were late 
initiators of anti-TNF (>2 years) (Fig. 1). The median period 
from UC diagnosis to the first anti-TNF agent in all 698 pa-
51 million people in Korean National Health Insurance claims database
17167 new UC patients identified between 2010–2016
1125 UC patients used anti-TNF agents
698 UC patients (399 early initiators and 299 late initiators)
Exclusion
• 419 patients who received anti-TNF therapy for less than 6 months
•  8 patients who had abdominal surgery before the start of anti-TNF 
therapy
Table 1. Baseline Characteristics of the Study Population 
Characteristics
Early initiators of anti-TNF agents
(n=399)
Late initiators of anti-TNF agents
(n=299)
p value
Sex, male 255 (63.9) 191 (63.9) 1.000
Age at diagnosis of UC (yr) 36.4±16.1 39.7±15.0 0.006
Age at anti-TNF agent initiation (yr) 37.3±16.1 43.1±15.1 <0.001
Period from UC diagnosis to first anti-TNF agent use (yr) 0.9±0.6 3.4±1.1 <0.001
Anti-TNF agent use duration (yr) 2.0±1.4 1.6±1.0 <0.001
First anti-TNF agent <0.001
Infliximab 264 (66.2) 156 (52.2)
Adalimumab 118 (29.6) 124 (41.5)
Golimumab 17 (4.2) 19 (6.3)
Medication use at anti-TNF agent initiation
5-ASA 277 (69.4) 191 (63.9) 0.144
Steroid 176 (44.1)   97 (32.4) 0.002
Immunomodulator 175 (43.9) 129 (43.1) 0.911
Concomitant immunomodulators (±30 days) 240 (60.2) 189 (63.2) 0.457
Previous immunomodulator exposure 288 (72.2) 253 (84.6) <0.001
Region at first anti-TNF agent use 0.016
Seoul 156 (39.1) 145 (48.5)
Outside Seoul 243 (60.9) 154 (51.5)
Hospital size at first anti-TNF agent use 0.010
Tertiary 269 (67.4) 229 (76.6)
General/community/clinic 130 (32.6)   70 (23.4)
5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor; UC, ulcerative colitis.
Data are presented as number (%) or mean±SD.
Fig. 1. Patient enrollment flow chart. UC, ulcerative colitis; TNF, tumor 
necrosis factor.
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tients was 1.7 years (interquartile range, 0.8–2.9 years). Among 
the 399 early initiators, 264 (66.2%), 118 (29.6%), and 17 (4.2%) 
patients started with infliximab, adalimumab, and golimum-
ab, respectively; among the 299 late initiators, 156 (52.2%), 124 
(41.5%), and 19 (6.3%) patients started with infliximab, adali-
mumab, and golimumab, respectively (p<0.001). The propor-
tion of patients who started with infliximab was higher in early 
initiators than in late initiators. 
Table 1 shows the baseline characteristics of early and late 
initiators of anti-TNF. Sex did not differ between the two groups. 
Age at diagnosis of UC and at the start of anti-TNF was younger, 
and the mean period of anti-TNF use was longer in early ver-
sus late initiators. The rate of steroid use at the start of anti-TNF 
was higher in early initiators than in late initiators. The rate of 
concomitant immunomodulator use did not differ between 
early and late initiators, whereas the rate of previous immuno-
modulator exposure was lower in early initiators than in late 
initiators. The proportion of patients who first started anti-TNF 
in the Seoul region and at tertiary hospitals was lower in early 
versus late initiators. 
Comparison of clinical outcomes between early and 
late initiators 
The rates of colectomy, ER visits, hospitalization, and cortico-
steroid use (per 100 patient-years) were not significantly dif-
ferent between early and late initiators (Table 2). The median 
time to colectomy, ER visit, hospitalization, and corticosteroid 
use after anti-TNF initiation also did not differ significantly be-
tween early and late initiators. Only five patients underwent 
colectomy during the study period (four early, one late initiator). 
Fig. 2 compares the clinical outcomes of Kaplan-Meier meth-
od and log-rank test. There were no significant differences in 
the cumulative probabilities of colectomy (p=0.415) (Fig. 2A), 
UC-related ER visits (p=0.967) (Fig. 2B), or corticosteroid use 
(p=0.789) (Fig. 2D) between early and late initiators. However, 
early initiators showed significantly higher cumulative proba-
bilities of hospitalization compared to late initiators of anti-
TNF (p=0.041) (Fig. 2C). 
Cox proportional hazard regression analysis of factors 
associated with clinical outcomes
The HRs of univariate and multivariable Cox proportional haz-
ards models are summarized in Table 3. Univariate analysis 
showed that late initiation of anti-TNF therapy was associated 
with a reduced risk of hospitalization (HR, 0.75; 95% CI, 0.57–
0.99). However, the significant association disappeared after 
adjusting for confounding variables [adjusted HR (aHR), 0.76; 
95% CI, 0.57–1.01]. Additionally, on multivariable Cox regres-
sion analysis, there were no significant differences in the risk 
of colectomy (aHR, 0.41; 95% CI, 0.04–3.90), ER visits (aHR, 
0.98; 95% CI, 0.50–1.92), and corticosteroid use (aHR, 1.04; 95% 
CI, 0.71–1.50) between early and late initiators. 
Anti-TNF use period (years) was associated with a reduced 
risk of hospitalization (aHR, 0.56; 95% CI, 0.43–0.74) and ste-
roid use (aHR, 0.65; 95% CI, 0.48–0.88). The use of 5-ASA at 
the start of anti-TNF was associated with an increased risk of 
steroid use (aHR, 2.61; 95% CI, 1.25–5.41).
DISCUSSION
This nationwide population-based study was able to confirm 
that UC patients receiving early anti-TNF therapy had similar 
clinical outcomes to those of late initiators. More specifically, 
Table 2. Outcomes of Early versus Late Initiators of Anti-TNF Agents 
Outcome 
Early initiators of anti-TNF agents
(n=399)




Colectomy (n, %) 4 (1.0) 1 (0.3) 0.399
Surgery rate (per 100 patient-years, 95% CI) 0.42 (0.13–0.98) 0.19 (0.01–0.84) 0.479
Median time to surgery (yr, IQR) 1.37 (0.66–2.13) 1.64 (1.64–1.64) 1.000
ER visit outcomes 
ER visit (n, %) 26 (6.5) 15 (5.0) 0.502
ER visit rate (per 100 patient-years, 95% CI) 2.76 (1.83–3.96) 2.91 (1.67–4.65) 0.870
Median time to ER visit (yr, IQR) 0.99 (0.38–2.04) 0.96 (0.64–2.18) 0.936
Hospitalization outcomes
Hospitalization (n, %) 143 (35.8) 77 (25.8) 0.006
Hospitalization rate (per 100 patient-years, 95% CI)   21.73 (18.36–25.49)   18.75 (14.87–23.26) 0.298
Median time to hospitalization (yr, IQR) 0.27 (0.11–0.90) 0.40 (0.13–0.79) 0.664
New steroid use (after 2 months) outcomes
New steroid use (n, %) 74 (18.6) 50 (16.7) 0.600
New steroid use rate (per 100 patient-years, 95% CI)   8.91 (7.03–11.10) 10.97 (8.20–14.29) 0.258
Median time to new steroid use (yr, IQR) 0.60 (0.27–1.14) 0.64 (0.31–1.19) 0.941
CI, confidence interval; ER, emergency room; IQR, interquartile range; TNF, tumor necrosis factor.
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we found no significant differences in the risk of colectomy, 
ER visits, hospitalization, or corticosteroid use between early 
and late initiators of anti-TNF therapy. Only three studies to 
date have directly evaluated the effect of earlier initiation of 
anti-TNF therapy on the clinical outcomes of UC. Similar to 
our results, none of those studies found more favorable out-
comes of early versus late initiators.12-14 A retrospective Hun-
garian study involving 42 UC patients demonstrated no differ-
ence in hospitalization or colectomy rate with time to anti-
TNF exposure.12 Similarly, a Dutch population-based study of 
66 CD patients and 16 UC patients observed no beneficial ef-
fect of early anti-TNF initiation (<16 months) versus late anti-
TNF initiation (>16 months) with respect to surgery, abscess 
formation, fistula formation, extraintestinal manifestations 
(EIMs), or mucosal healing.13 However, in this Dutch study, 
CD and UC were analyzed together. A retrospective Canadian 
study of 115 UC patients (78 infliximab, 37 adalimumab) also 
revealed that early anti-TNF initiation, defined as starting treat-
ment within 3 years of diagnosis, was not associated with col-
ectomy (aHR, 2.02; 95% CI, 0.57–7.20), hospitalization (aHR, 
1.66; 95% CI, 0.84–3.30), or secondary loss of response (aHR, 
0.86; 95% CI, 0.52–1.42).14 However, drawing a firm conclusion 
from the results of these three prior studies is difficult, as the 
number of included patients was too small. Since our study 
included a relatively larger sample size (698 patients), it can 
more reliably support the results of previous studies showing 
no benefit of earlier anti-TNF initiation in UC patients. Our 
findings are also in line with those of a recent U.S. study that 
evaluated the effects of vedolizumab stratified by disease dura-
tion.18 In this study, UC patients treated early with vedolizumab 
(≤2 years, n=109) did not show different rates of clinical remis-
sion, corticosteroid-free remission, or endoscopic remission 
Cumulative rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Within 2 year 0.6 1.0 1.5 1.5 1.5 1.5 -
More than 2 year 0.0 0.7 0.7 0.7 - - -
Cumulative rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Within 2 year 3.4 5.7 7.4 9.9 12.4 12.4 -
More than 2 year 3.6 5.0 9.9 9.9 - - -
Cumulative rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Within 2 year 28.8 34.8 41.9 45.0 49.5 49.5 -
More than 2 year 23.5 29.1 35.2 35.2 - - -
Cumulative rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Within 2 year 14.1 18.0 21.8 24.6 27.2 27.2 -
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Fig. 2. Kaplan-Meier survival analysis of clinical outcomes from initiating anti-tumor necrosis factor agents. (A) Cumulative probabilities of intestinal 
surgery. (B) Emergency room visits. (C) Hospitalization. (D) New steroid use. UC, ulcerative colitis.
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from those who were treated late with vedolizumab (>2 years, 
n=328).18
These results are in contrast with evidence from studies of 
CD in which early anti-TNF initiation improved clinical out-
comes, such as reducing the risk of bowel stricture develop-
ment or abdominal surgery.9-11,19 Although the reason for the 
difference in the effect of early anti-TNF therapy between UC 
and CD cannot be clearly elucidated, there are several poten-
tial explanations. First, differences in the pathophysiological 
mechanisms of UC and CD may be a contributing factor. In 
CD, early control of the inflammatory burden with aggressive 
medical treatment reduces the development of irreversible 
mechanical complications, such as fibrostenotic strictures and 
penetrating disease, that require surgical treatment.9,19 In con-
trast, UC is characterized by mucosal rather than transmural 
inflammation; therefore, fibrostenotic or penetrating disease 
is very rare.20 Patients with UC usually require colectomy due 
to refractoriness to medical treatments or the development of 
colorectal cancer (CRC) or colorectal dysplasia rather than me-
chanical complications. One of the reasons for early anti-TNF 
treatment showing no beneficial clinical outcome in patients 
with UC may be that patients with UC are much less likely to 
develop irreversible bowel damage than those with CD. Sec-
ond, symptom differences between UC and CD may also be a 
contributing factor. UC flares usually present dramatically with 
bloody diarrhea, urgency, and tenesmus, which are difficult 
to overlook. A Japanese study demonstrated that self-reported 
symptoms by patients are useful to estimate endoscopic activ-
ity in UC.21 In contrast, patients with CD are often asymptom-
atic, even in uncontrolled CD-related inflammation condi-
tions, reducing the likelihood that they receive medical attention 
or undergo hospitalization.22 Given these differences, it may 
be more difficult to determine the appropriate timing of anti-
TNF initiation in CD than in UC; for patients with CD, the tim-
ing may depend largely on the physician’s decision. Indeed, 
our preceding studies showed that variation in the prescription 
rate of anti-TNF agents was greater in CD than that in UC.17 
Since clinical symptoms better reflect the real severity and in-
flammatory burden of UC than CD, delays in anti-TNF treat-
ment may occur less often in UC than in CD, and early anti-TNF 
treatment may be less helpful in UC than in CD. Our findings 
suggest that, for patients with UC, a conventional step-up strat-
egy may be more reasonable than top-down or accelerated 
step-up strategies. Third, there might be differences in disease 
severity between early and late initiators of anti-TNF therapy. 
Patients requiring early anti-TNF therapy are more likely to have 
more severe disease. Indeed, in the aforementioned Canadian 
study, patients treated with early anti-TNF therapy had more se-
vere endoscopic disease at anti-TNF therapy induction (mean 
Mayo endoscopy subscore, 2.46 vs. 1.86; p<0.001); when adjust-
ed for endoscopic disease activity, the timing of anti-TNF initi-
ation did not affect the risk of colectomy or hospitalization.14 
Likewise, in our study, early initiators may have had more se-
vere disease than late initiators, although information on dis-
ease severity was not captured in the HIRA database. High 
steroid use and younger age at the start of anti-TNF in early 
initiators (Table 1) may support our hypothesis. UC patients 
with severe serologic and endoscopic activities reportedly 
have poor prognosis, such as an increased risk of colectomy 
and hospitalization.23,24 Given that anti-TNF therapy for early 
initiators with more severe disease who have poorer outcomes 
may equalize the clinical outcomes of late initiators with less 
severe disease, early anti-TNF therapy may have been helpful 
for early initiators. Based on our findings, the necessity of early 
anti-TNF agent use should not be overlooked, even in UC pa-
tients with severe activity who do not respond to corticosteroids 
or immunomodulators in the early disease stages. There is 
strong evidence that anti-TNF agents should be used early as a 
rescue therapy for corticosteroid-refractory patients with se-
vere or fulminant UC.23 However, our results suggest that, con-
versely, other therapeutic options, such as 5-ASAs and immu-
nomodulators, should be optimized for patients with mild to 
moderate disease. It is also important to select patients who are 
more likely to develop stenosis or CRC, so that anti-TNF use is 
not delayed in these high-risk patients. Fourth, longer follow-
up periods may be needed to observe disease modifications in 
UC. In this study, we only examined data from 2010 to 2016. 
Whether early intervention with anti-TNF agents can change 
the natural course of UC should be explored further in long-
term longitudinal studies.
Interestingly, we found that the use of 5-ASA at the start of an-
ti-TNF was associated with an increased risk of steroid use. 
Although it is difficult to explain the reasons for this result in a 
clear manner, a possible explanation is that this drug might 
have been discontinued in patients whose prognosis was ex-
pected to be good. In addition, some patients may have discon-
tinued 5-ASA due to side effects, and they might have received 
an earlier step-up therapy with immunomodulators or anti-
TNF agents, although the disease activity is not severe.
To the best of our knowledge, this is the largest study to date 
to assess the impact of early initiation of anti-TNF on the clini-
cal outcomes of UC patients. Furthermore, this is also the first 
population-based study on this topic in Asia. Nonetheless, our 
study had several limitations. First, disease extent and severity 
(e.g. clinical, serologic, and endoscopic activities), which can 
affect clinical outcomes, were not considered, as these infor-
mation could not be captured in the HIRA database. Although 
anti-TNF agents are approved only for patients with moderate 
to severe disease activity (Mayo score, 6–12; endoscopy sub-
score≥2) in South Korea, due to the non-randomized design 
of this study, early initiators might have had more severe and 
extensive diseases than late initiators did. Therefore, the ef-
fects of early anti-TNF use might have been offset. Second, de-
tailed clinical outcomes, such as mucosal healing, EIMs, com-
pliance with the use of anti-TNF, loss of response requiring 
anti-TNF agent dose escalation, and reasons for discontinua-
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tion of anti-TNF therapy, were not assessed. Third, we did not 
evaluate the safety issue and cost effectiveness according to 
anti-TNF induction timing. Fourth, we did not verify the accu-
racy of UC diagnosis and UC-related ER visits. Although we 
defined ER visits as patient visits to the ER with UC as the pri-
mary diagnosis, it may be difficult to accurately view them as 
true UC-related ER visits. However, we consider our definition 
of UC diagnosis to be quite reliable. When defining UC, we 
considered the prescription of UC medications as well as the 
diagnostic code. Moreover, our study included only patients 
who received anti-TNF therapy from a gastroenterology clinic 
to rule out the use of anti-TNF agents for other autoimmune 
diseases. Finally, although our study included the largest num-
ber of UC patients, there were limitations in comparing the 
colectomy rates. Since colectomy is very rarely required in UC, 
much larger cohorts are needed to increase the statistical pow-
er to determine the difference in colectomy rates.
In conclusion, similar clinical outcomes, including colecto-
my, ER visits, hospitalization, and the need for corticosteroids, 
were observed for early and late initiators of anti-TNF therapy 
among South Korean patients with UC. These results suggest 
that indiscriminate early anti-TNF treatment should be avoid-
ed for patients with UC. The timing of anti-TNF initiation must 
be carefully determined for each patient according to the dis-
ease severity and refractoriness to other therapeutic options. 
Further long-term large-scale studies are warranted to clarify 
the ability of early use of anti-TNF agents to alter the natural 
course of and prevent disease progression in UC. 
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